Ambit Biosciences signs drug-development deal with Astellas

12/23/2009 | North County Times (Temecula, Calif.)

Astellas Pharma will pay Ambit Biosciences $40 million upfront and as much as $350 million in milestone fees as part of a drug-development collaboration. The partnership covers an acute myeloid leukemia treatment, which is in midstage trials, and other drugs that target an enzyme called FLT3 kinase.

View Full Article in:

North County Times (Temecula, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD